News Hub | News Direct

ALDER HEY AND NEEDLESMART PARTNERSHIP AIMS TO REDUCE 100,000 NEEDLESTICK INJURIES TO NHS HEALTHCARE WORKERS

NeedleSmart

BRITISH SMART MEDTECH COMPANY INVENTS WORLD’S FIRST END-TO-END SAFE NEEDLE DESTRUCTION TECHNOLOGY TECH AIMS TO REDUCE 3 MILLION GLOBAL NEEDLESTICK INJURIES In a recent survey*, it was reported that a staggering 94 per cent of practising surgeons i n the UK have either been personally affected by a needlestick injury (NSI) or have seen a colleague experience one. The Royal College Of Nursing also reported last year that the pressures of the pandemic and lack of training accounted for a 50% rise in sharps injuries. UK based smart med-tech innovator NeedleSmart aim to change this statistic. NeedleSmart has designed the world’s first end-to-end vaccination and safe needle destruction system aimed at reducing the 100,000 needlestick injuries (NSI) to NHS workers in the UK each year and 3 million globally. Of the 100,000 reported cases of NSI**, NHS healthcare workers in the UK are the most affected profession, with 500,000 NSI in Germany and more than 1 million NSI in the USA. They are estimated to cost each NHS trust £500,000 each year*** and an estimated £127 million across England ****. This is not to mention the impact it has on staff absenteeism, the cost of bringing in replacement staff and legal litigation to NHS trusts, which are already under increased pressure with the pandemic. To achieve this the Knowsley-based MedTech disruptor have entered into an exciting new innovation partnership with the world-renowned Alder Hey Children’s NHS Foundation Trust, one of Europe’s leading paediatric healthcare institutions with a unique dedicated innovation centre focused on solving real world problems faced day to day. The first phase of that innovation partnership will work on a safety and needlestick injuries (NSI) reduction programme as part of its clinician and patient safety enhancement. The project aims to impact, reduce and eventually prevent the 100,000 NSI that occur every year to NHS healthcare staff. In its wider remit, NeedleSmart is also working with 15 NHS trusts across the UK as part of the nationwide pilot, where its focus is shared between safety enhancement, carbon reduction and sustainability. This programme is breaking new ground on the art of the possible with regards to medical waste disposal resulting is direct carbon savings as part of the NHS sustainability initiative. Alder Hey is widely recognised for its cocreation and adoption of new innovative technologies and boasts the largest hospital-based Innovation Centre in the UK with 25+ full time innovation experts working out of a 1000sqm Innovation Hub in the heart of the hospital. Through this alliance, Alder Hey will work directly with NeedleSmart as it brings its multi-faceted hardware and software solutions to the healthcare markets. Alder Hey will work shoulder-to-shoulder with the team at NeedleSmart in a co-development plan that consists of three phases: Clinician and patient safety enhancement Sustainability to recycling pilot Clinical workflow and data transactions NeedleSmart, working in conjunction with British engineering solutions company CAL International, has designed and innovated a patented needle destruction system. Not only does this destroy the hypodermic needle, but also provides a full audit trail of each needle, charting the journey from its initial deployment, through to its assignment to healthcare staff, injection to patient and ultimately its safe destruction. The NeedleSmart Pro device destroys the contaminated needle in a sealed chamber in just six seconds, effectively minimising post-procedural NSI. The NeedleSmart device heats the needles inserted into the chamber to 1,300 degrees Celsius, which will kill potential harmful pathogens, viruses and bacteria adhering to the needle. Within seconds the needle is compressed into a tiny ball and released from the NeedleSmart device as a safe sphere of metal at the tip of the syringe. NeedleSmart have recently achieved FDA approval as a Class II medical device, making NeedleSmart the first UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD)), allowing the MedTech disruptor to expand into the US market and other global territories. Commenting on the new safety partnership with Alder Hey Children’s NHS Foundation Trust, NeedleSmart CEO and smart MedTech disruptor, Cliff Kirby, said: “We are absolutely delighted to be working with Alder Hey Children’s NHS Foundation Trust on this unique innovation partnership, with its first phase aimed at clinician and staff safety around needlestick injuries (NSI). There is a massive issue for the NHS around the safety of healthcare staff. The wider implications of NSI include the costs of medical treatment for the injured healthcare worker, the costs of substitute staff and costly litigation, all while the NHS is under immense pressure dealing with the pandemic.” Claire Liddy, Managing Director of Innovation at Alder Hey Children’s NHS Foundation Trust, said: “At Alder Hey, we want to ensure that we are always standing at the leading edge of clinical innovation and safety. NeedleSmart’s product solution offers a number of innovation drivers to build from starting with clinician and patient safety around the major issue of needlestick injuries, carbon reduction and data transactions. Working alongside the team at NeedleSmart, we are constantly challenging conventional thinking around sharps disposal and what benefits could be achieved at that moment. We want to work with businesses that have the potential to make a real difference. At the heart of Alder Hey is a commitment to innovate – we dare to think differently, We build areas of technical strength and excellence and scan the horizon for cutting-edge technology that can positively impact healthcare, we work with a select number of partners that share our drive and vision – and NeedleSmart is one such business. At a time when co-worker safety, sustainability and innovation are so important, disruptive technologies have a critical role to play. We have been assessing the viability of NeedleSmart in the background during our first Covid-19 vaccination programme – and we are delighted to be working together with NeedleSmart to reduce the occurrence and impact of needlestick injuries across the NHS as we work through the daily challenges presented by the pandemic.” NeedleSmart’s Cliff Kirby added: “Coming from a product development background, I know all too well that any product only succeeds with the blessing and input of the end user. This ethos sits at the centre of the Alder Hey Innovation Centre and we are really excited to work with the team on a co-development strategy that could have such a huge and positive impact in the medical environment. Having watched the team at Alder Hey deliver the first rounds of Covid-19 vaccinations, it is an absolute privilege to be associated with an organisation that quite clearly takes a challenge head on and delivers a solution in a way that is second to none. The development work with Alder Hey provides critical use case information to support the national level programme targeting sustainable carbon reduction in this space to the wider NHS sustainability target of carbon net zero by 2040 within the NHS.” ENDS For all press and media enquiries, please contact Head Of Global PR & Communications - Gerard Franklin @i5 Media e: gerard@i5media.co.uk m: 07791 039636 For more information on NeedleSmart, visit www.needlesmart.com www.digitalvaccination.com The NeedleSmart process explainer https://youtu.be/C968RkWtSi8 The NeedleSmart DVS explainer https://www.youtube.com/watch?v=nIAzsMwyBDc NOTES TO EDITORS ABOUT NEEDLESMART NeedleSmart is a market leading, British patented needle destruction technology engineered in the UK with offices in Knowsley, and Pittsburgh, Pennsylvania. Their award-winning NeedleSmart PRO needle destruction device has achieved FDA approval as a Class II medical device, being the first UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD)). As well as contributing to the reduction of needlestick injuries and their consequential costs, the NeedleSmart process has the potential to reduce the cost and increase efficiency of used needle disposal. NeedleSmart’s innovative technology also offers the opportunity to move hypodermic needles, syringes and consumables associated with the injection/vaccination process, away from conventional sharps bins to a solution that allows recycling to become a possibility. NeedleSmart technology compresses the needle, significantly reducing the needle footprint leading to a minimum of 50% increase in needle count per sharps bin. After the unexpected Covid-19 pandemic and the mass vaccination programme that followed, NeedleSmart's DVS (Digital Vaccination System) was created to support mass vaccination programmes, digitalising the vaccination process with every detail being automatically recorded in the cloud. DVS delivers a single solution that can coordinate every individual vaccination initiative into a single, coherent vaccination programme ABOUT ALDER HEY INNOVATION CENTRE – Todays Child, Tomorrows Healthier Adult Alder Hey Innovation is the largest, dedicated, purpose built, hospital led innovation centre in the UK. Alder Hey Children’s NHS Trust has a proud history of innovation spanning over a hundred years. Today we continue that legacy pioneering the use of cutting-edge technology and innovating to save lives and improve the life chances of today’s child. Our ambition is to be the world leader in advancing child health with innovation, utilising our unique hospital-based innovation centre, disrupting, discovering and disseminating to have real impact. Our mission is to solve the real-world healthcare problems children and young people face today, creating fair access to care and enabling a healthier future for all. Our unique strengths lie in our experience to innovate and disrupt, with a strong track record of rapid problem solving, creating an end-to-end pipeline and process from problem identification and solutions through to commercial income. Our strategy is fueled by a bespoke open innovation system, to rapidly identify real-world problems and bring the right partners together to solve those with innovative and disruptive technology. Our co creation approach involves scouting and partnering with local and international industry and academia, bringing the most innovative technology and solutions to Alder Hey, where we strive for excellence and breakthroughs in healthcare. www.alderheyinnovation.com ABOUT ALDER HEY Alder Hey Children’s NHS Foundation Trust provides care for over 330,000 children and young people every year. Alder Hey delivers clinical excellence for all children, for routine illnesses as well as very complex and rare conditions. One of four stand-alone children’s hospitals in the UK, it is a national centre for neuro and craniofacial surgery, a regional centre for burns injuries and a Centre of Excellence for children with cancer, heart, spinal and brain disease. Alder Hey as an NIHR funded Clinical Research Facility (CRF) that specialises in the design, and delivery, of early phase drug trials in children with a wide range of conditions. The Trust is one of only four epilepsy surgical centres in the UK and one of only two accredited major trauma centres in the North West. Alder Hey is also a respiratory Extracorporeal Membrane Oxygenation (ECMO) surge centre and is the referral centre for the treatment of congenital heart defects in North West England, North Wales and Isle of Man. It became the first UK Centre of Excellence for Childhood Lupus in 2010. Alder Hey is the first accredited Investing in Children hospital in the UK. It has a dedicated patient experience programme which includes the award-winning Alder Hey Arts involving music therapy, dance programmes, storytelling and animation projects. It is also one of a few hospitals to have a Children and Young Person’s Forum. Alder Hey opened a new hospital ‘Alder Hey in the Park’ in 2015. Europe’s first hospital in a park, the new facility provides a purpose-built, unique and world class healing environment for children and young people. Alder Hey is supported by The Alder Hey Children’s Charity which aims to raise vital funds for lifesaving equipment, research projects and patient experience initiatives. For more information visit www.alderhey.nhs.uk and www.alderheycharity.org Reference Points *Survey conducted by SERMO. 510 actively practicing UK, US, German, Swedish, Japanese and Australian surgeons responded to a survey on the importance of surgical gloves. April 2019. ** A review of sharps injuries and preventative strategies, Journal of Hospital Infection, 2003 *** Needlestick Injury in 2008, Royal College of Nursing, 2008 **** NHS statistics, facts and figures. July 2017. http://www.nhsconfed.org/resources/key-statistics-on-the-nhs. There are 254 NHS Trusts in the UK, so the estimated cost is calculated to be £127m (£500,000 x 254) Contact Details i5 Media Gerard Franklin +44 7791 039636 gerard@i5media.co.uk

January 19, 2022 06:50 AM Eastern Standard Time

Image

Hong Kong Baptist University research reveals that bisphenol S exposure may promote breast tumour progression and increase cancer risk

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 18 January 2022 - A study led by Hong Kong Baptist University (HKBU) has revealed that different degrees of exposure to bisphenol S (BPS), an industrial chemical widely used in paper products and plastic containers, are associated with the growth and deterioration of breast tumours in a mouse model. The research results suggest the need for more in-depth and comprehensive research on the potential negative impact of BPS on human health, and the ongoing search for a safer alternative for use in industrial production may be warranted. A research team led by Professor Cai Zongwei, Chair Professor of the Department of Chemistry and Director of the State Key Laboratory of Environmental and Biological Analysis at HKBU, has revealed that different degrees of exposure to bisphenol S are associated with the growth and deterioration of breast tumours in a mouse model. Apart from the HKBU scientists, the research team also included researchers from the Shenzhen Institute of Advanced Technology at the Chinese Academy of Sciences and Xi’an Jiaotong University. The research results have been published in the Journal of Hazardous Materials, an international scientific journal. Association between BPS and breast cancer under-researched In the past, bisphenol A (BPA) was widely used in the production of a diverse range of products, such as baby bottles, food and beverage containers, and the thermal paper used for printing receipts. As previous research has shown an association between BPA exposure and human endocrine system disruption, metabolic disease and an increased risk of breast cancer in recent years, scientists have looked for alternatives to BPA, and BPS has been used as one of the substitutes. Despite reports on the adverse effects of BPS on human health, its impact on tumour progression and how it disrupts the relevant metabolic processes in breast cancer remain poorly understood. A research team led by Professor Cai Zongwei, Chair Professor of the Department of Chemistry and Director of the State Key Laboratory of Environmental and Biological Analysis at HKBU, carried out several experiments to explore how BPS exposure at environmentally relevant levels affects the development of breast tumours, including the tumour’s morphological characteristics as well as lipid and protein distribution, with the aid of mass spectrometry imaging technology. BPS exposure increases tumour volume and weight The research team conducted experiments on three groups of mice model that had been transplanted with human breast cancer cells. In the first dosing group (BPS-10 group), the mice were fed daily with a lower dosage of 10 micrograms of BPS per kilogram of body weight for eight weeks. In the second group (BPS-100 group), the mice were fed with a higher dosage of 100 micrograms of BPS per kilogram of body weight. The mice in the control group were fed olive oil. Tumour proliferation in the mice was then investigated, and the team used morphological analysis to study the breast tumour tissue. In general, increases in tumour volume and weight represent proliferation of tumour tissues. When a tumour further develops, the condition of its necrotic region and its peripheral tissues will change. However, the volume and weight of the tumour may reduce as a result of changes in the conditions of the tissues. After the eight-week experiment, the average volume and weight of the tumours in the BPS-10 group were 13 times and 11 times higher than that of the control group respectively, and the average volume and weight of the tumours in the BPS-100 group were 4 times and 4.5 times higher than that of the control group respectively. Therefore, the results show that exposure to BPS was closely related to the proliferation and deterioration of breast tumours. Different dosages associated with tumour proliferation and deterioration The research team analysed the necrotic region and neoplastic region of the breast tumours in the three groups of mice. The two regions are common pathological features of solid tumours. An increase in the relative proportion of the necrotic region reflects the proliferation of the tumour, while an extended neoplastic region indicates the deterioration of the tumour. In the control group, the status of tumour cells in the necrotic region and the neoplastic region was stable, and the mice from the group showed no significant tumour proliferation and deterioration after the experimental period. However, in the two BPS treated groups, an increase in tumour size was observed along with changes in the arrangement and distribution of tumour cells conducive to tumour proliferation and deterioration. After the experiment, the necrotic regions in the BPS-10 and the BPS-100 groups accounted for 54.7% and 11.5% of the average section area of the tumours respectively. The results indicate that a low dosage of BPS induces faster tumour growth, and a high dosage of BPS may ultimately lead to deterioration of the tumour, as shown by the relatively small average size of the necrotic region and the extended neoplastic tissue in the BPS-100 group. BPS affects the distribution of tumour-related lipids and proteins The research team identified six lipid biomarkers that regulate tumour growth. With the analysis of tumour tissues’ morphological characteristics and the use of mass spectrometry imaging, it was found that in the two BPS-exposed groups, these lipids were highly abundant in the necrotic regions of breast tumours when compared with the control group. The team inferred that the metabolism of these tumour-regulating lipids was interrupted in the breast tumours following exposure to BPS. The team also discovered the distribution of twelve protein biomarkers, including the proteins associated with breast tumour proliferation and deterioration. The results demonstrate the important function of BPS exposure-related lipids and proteins, and future research will further explore their role in breast cancer. BPS may increase human breast cancer risk The research team then compared the distribution of lipids and proteins in the BPS-exposed mice groups with those observed in human breast cancer tissue samples, and similar patterns were identified. While not all tumours will become cancerous, based on the benchmark results, the team deduced that exposure to BPS will increase the risk of breast cancer in humans. “BPA was replaced by the less studied chemical BPS in industrial production. Our research findings show that BPS may potentially be associated with breast tumour proliferation, and further study is deemed necessary to unveil more about the chemical’s possible negative impact on human health. In the long run, industry may need to identify safer substitutes for both BPA and BPS. Policymakers should also establish relevant safety standards and regulations for the use of BPS,” said Professor Cai. Contact Details Hong Kong Baptist University Winnie Shum from the Communication and Public Relations Office +852 3411 5262 hkbunews@hkbu.edu.hk Company Website https://www.hkbu.edu.hk/

January 18, 2022 08:00 AM Eastern Standard Time

Image

Elsevier appoints Laura Hassink as Managing Director, STM Journals

Elsevier

Elsevier, a global leader in research publishing and information analytics, is pleased to announce the appointment of Laura Hassink as the new Managing Director for STM Journals, succeeding Philippe Terheggen, who has retired at the end of 2021 after a distinguished 30-year career at Elsevier. Laura will be responsible for Elsevier's portfolio of 2,650 journals managed by more than 24,000 editors, who collectively publish more than 560,000 research articles a year. Laura is currently Elsevier’s Senior Vice President of Publishing Transformation, overseeing all aspects of operational support for its journals, improving, and innovating the publication experience for authors, peer reviewers and editors. Laura has also been instrumental in accelerating Elsevier’s substantial progress in open access publishing, with the company now offering more than 600 gold open access journals, as well as offering open access publishing options across all its portfolios. Before her current role, Laura served as SVP Product Management for ScienceDirect and Journal Branded Solutions, responsible for defining the strategy and product roadmap to improve customers’ reading experience and visibility of the journals Elsevier publishes. During her 24 years with Elsevier, she also served as SVP Physical Sciences in STM Journals and held positions in Strategy, Business Development and Journal Services. Since 2015, Laura has been active as a board member of the Dutch Publishers Association, Mediafederatie and Chair of the Media Voor Vak en Wetenschap (MVW), and serves as Chair of the Open Science Forum. She holds a Master’s degree in Economics from Vrije Universiteit, and a Bachelor's degree in Business Administration from Nyenrode Business Universiteit. Elsevier’s CEO, Kumsal Bayazit, commented on the appointment: “Laura has a genuine passion for understanding the needs of the research communities we serve and maintaining the highest quality and integrity standards in scholarly communications. She is also the perfect leader to continue to build on Elsevier’s 140-year heritage as the global leader in scientific publishing, helping to ensure quality research contributes to societal progress.” About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Media contact Andrew Davis Elsevier Communications +44 7393 242 466 andrew.davis@elsevier.com Contact Details Elsevier Communications Andrew Davis +44 7393 242466 andrew.davis@elsevier.com Company Website https://www.elsevier.com/

January 17, 2022 05:16 AM Eastern Standard Time

Image

G Medical Innovations (NASDAQ: GMVD) is forecasting incremental Q1 revenues at around $30 MM, based on revenue generated from G Medical Tests and Services’ physical storefront testing locations

G Medical Innovations Holdings

Dr. Yacov Geva, President and CEO of G Medical Innovations, and Michael McDade, CEO of McDade Products, LLC, announced today that they acquired an undisclosed number of shares of G Medical Innovations (NASDAQ: GMVD). The CEO of McDade Products, LLC cited high confidence levels for sales of the co-branded LiveNow COVID-19 PCR Test Collection Kits announced this week and the forecasting of $30MM in revenues generated from the successful storefront COVID-19 testing locations operated by the company’s G Medical Tests and Services division. G Medical Tests and Services currently operates storefront testing locations in California. During the next few months, the company expects to expand its network of storefront testing locations in California and other U.S. regions to be announced at a later date. Pittsburgh-based McDade Products, LLC and G Medical Tests and Services have partnered to make millions of FDA EUA-approved COVID-19 PCR collection test kits available for retailers to sell by the end of January, in response to a national shortage of COVID-19 test options. The LiveNow COVID-19 PCR Test Collection Kits provide 24–48-hour certified lab results and retail for $9.99. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. “With the U.S. government’s shift to emphasize COVID-19 testing to combat this virus, I’ve acquired stock with G Medical on the open market because I strongly believe in the future of the company. As a trusted and proven mobile health and e-health company, G Medical is now making SARS-CoV2 certified lab testing even more accessible and convenient for consumers,” said Michael McDade, CEO of McDade Products, LLC. McDade Products is a division of McDade Group, a privately held specialty sales, marketing, and distribution company serving the U.S. retail industry. About McDade Group Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses delivery of purchase orders and anticipated gross profits. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Investor Relations CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 14, 2022 07:00 AM Eastern Standard Time

McDade Products, LLC and G Medical Tests Secure Additional Purchase Order for $6.5 Million, Reflecting $3.5 Million Gross Margin, to be Delivered in Q1

G Medical Innovations Holdings

PITTSBURGH, PA – McDade Products, LLC and G Medical Tests and Services, a division of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD), today announced an additional $6.5 million purchase order for two million COVID-19 PCR collection test kits. G Medical will be selling these units wholesale for $3.25 each, reflecting a gross profit of approximately $3.5 million. Additionally, G Medical expects to be paid an average of $85.00 per test through each patient’s insurance. “McDade is pleased to be expanding upon its existing purchase order so quickly and expects to be ordering a further seven million test kits in the next thirty days.” These orders seem to come at a pertinent moment with the Biden Administration recently requiring that private insurers pay for a minimum of eight COVID 19 test kits per person per month starting January 15 th. G Medical Tests and Services is delighted to provide McDade with current and future purchase orders. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. About McDade Group Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses delivery of purchase orders and anticipated gross profits. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Investor Relations CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 12, 2022 07:00 AM Eastern Standard Time

Most Lives Saved by Organ Transplant in a Single Year

United Network for Organ Sharing

In 2021, a historic 41,354 organ transplants were performed in the U.S., an increase of 5.9 percent over 2020 and the first time the annual total exceeded 40,000, according to preliminary data from United Network for Organ Sharing (UNOS), the engine that powers the nation’s organ donation and transplantation system. The three organs most commonly transplanted also set annual records. There were 24,669 kidney transplants, 9,236 liver transplants and 3,817 heart transplants in 2021. Liver transplant totals have set annual records for the past nine years, and heart transplants have set a new record every year for the past decade. “We are gratified that transplantation continues to increase substantially and meet the needs of many more people with organ failure, despite ongoing challenges to healthcare relating to the COVID-19 pandemic,” said Matthew Cooper, M.D., FACS, president of the UNOS Board of Directors. “This speaks to the dedication and collaboration of donor hospitals, organ procurement organizations and transplant hospitals striving to ensure every opportunity to give the gift of life is pursued and celebrated." Thanks to the generosity of selfless donors and their courageous families, deceased organ donations continued its 11-year record trend. Increases in donation occurred in many areas throughout the nation. Of 57 organ procurement organizations (OPOs), 49 experienced an increase in donation over their 2020 total. Forty-five OPOs set all-time records for donors recovered in a single year. “As always, we are indebted to the many thousands of people who make these transplants possible through the selfless gift of organ donation,” Cooper said. “And we are reminded daily of our need to help the tens of thousands of men, women and children continuing to await a lifesaving transplant.” Learn more about organ donation and transplantation and how to register to be a donor at www.unos.org. Dr. Cooper is a transplant surgeon and the director of kidney and pancreas transplantation at MedStar Georgetown Transplant Institute at MedStar Georgetown University Hospital. About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN ) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

January 11, 2022 11:20 AM Eastern Standard Time

Image

GLOBAL INDUSTRY LEADER NEAL GUTTERSON JOINS GROUNDWORK BIOAG’S ADVISORY BOARD

Groundwork BioAg

Groundwork BioAg® expanded its advisory board with the addition of Neal Gutterson, PhD, Chief Technology Officer and Partner at Radicle Growth and recently retired Chief Technology Officer at Corteva. Recognized as a world-class scientist in agricultural biotechnology, Gutterson brings in-depth experience advancing innovation and biological platforms to deliver greater value to farmers around the world. “Innovation in biologicals and regenerative practices are helping to restore soil health and carbon permanence while ensuring plant nutrition, with less phosphorus fertilizer. But more must be done to accelerate mainstream adoption of these solutions and engage everyone across the food supply chain—from farmers to consumers—to restore overall sustainability. At Groundwork BioAg, this is our mission. We look forward to working with Neal as our advisor and are delighted to tap into his unique experiences,” said Dr. Yossi Kofman, Co-Founder and Chief Executive Officer at Groundwork BioAg. Prior to his role at Corteva, Gutterson led Mendel Biotechnology as CEO, where he expanded the company’s plant gene network platform to improve productivity, resource use efficiency and stress tolerance of key agricultural crops. Today, Gutterson serves as CTO and Partner at Radicle Growth and on the System Board of CGIAR. In the past, he has served on the Board of Directors for the International Maize and Wheat Improvement Center (CIMMYT) as well as several organizations focused on technology advancements that improve the overall sustainability of crop production. “Tremendous progress has been made to expand biological innovation in the last decade, however, to combat climate change and restore the overall health of our food supply, we must look deeper into our soils,” said Gutterson. “I’m delighted to join Groundwork BioAg’s advisory board to help the company achieve the full potential of its proven science, while tackling existential challenges like permanent soil carbon sequestration and chronic drought.” In 2021, Groundwork BioAg accelerated mass production of its highly concentrated, cost-effective mycorrhizal inoculants and unlocked its technology platform to quickly scale product development. The company has consistently delivered year-over-year sales growth and expanded its global presence. In addition to increasing yield, Groundwork BioAg’s mycorrhizal inoculants improve sustainability by reducing dependency on phosphorus fertilizer and improving carbon sequestration in soil. About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

January 11, 2022 08:00 AM Central Standard Time

Image

Biomedical AI entrepreneur Prof. Amir Geva appointed CSO of SleepX

Appyea

World renowned machine learning and bio-feedback expert joins company to execute and lead the development of DreamIT – the company’s patented solution integrating its proprietary AI technology in a wearable data driven wristband to treat sleep apnea and snoring. SleepX, a subsidiary of AppYea (OTC: APYP) focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announced today the appointment of Biomedical AI entrepreneur Prof. Amir Geva, as its chief science officer. Prof. Geva is a world-renowned expert in the field of machine learning, with over 25 years of business leadership experience as the founder and R&D teams leader of biomedical AI companies Elminda, InnerEye and WideMed. He brings over 40 years of deep AI research, serving today as the Head of the Biomedical Signal Processing and Machine Learning Lab and as Professor at the Electrical and Computers Engineering Department at Ben Gurion University of the Negev in Israel. As of today, Prof. Geva had published 62 scientific articles, and he is Senior Member at the Biomedical Engineering and Computers of the IEEE. In the past he had served also as consultant to the Israeli Air Force and Elbit on bioelectrical signal processing. He is DSc in Biomedical Engineering from the Technion Israel Institute of Technology, and formerly a Major at the Israeli Navy. "SleepX’ is the right solution many had been waiting for", Prof. Amir Geva commented. "The company has introduced a revolutionary combination of sensor technology, data analysis and machine learning to take on the challenge sleep-training for adults and improving people’s sleep and general wellbeing. I look forward to working with the team to complete the development of the company’s product and realize its market potential." SleepX is an Israeli research and development company recently acquired by AppYea. The company had developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to start serial production in 2022. The company currently focuses its activities on the development and commercialization of its flagship product DreamIT. "We are honored to have a world expert in bio-feedback and AI such as Prof. Geva joining us to lead the development of our product’s brain analysis capabilities and advance the execution of our go-to-market strategy to realize the company’s business plan", said Boris (Bary) Molchadsky, President and CEO of SleepX, and Chairman at AppYea. Contact Details AppYea Inc. Asaf Porat info@appyea.com Company Website http://www.appyea.com

January 11, 2022 08:24 AM Eastern Standard Time

Image

Elsevier launches Complete Anatomy female model, the most advanced full female anatomy model available in the world

Elsevier

The innovative 3D solution marks a major milestone in education equality with the representation of the full female anatomy in the study of the human body The launch is coming at a time when females are more likely to be misdiagnosed for health conditions compared to male counterparts Elsevier, a global leader in research publishing and information analytics, is pleased to announce the launch of the most advanced 3D full female model ever available, as part of the latest addition to its 3D platform, Complete Anatomy. This marks the first time that a female model has been built with this level of detail in its entirety, to represent the female — versus replacing specific areas of the male anatomy with female features. The solution allows educators to visualize, edit and teach anatomy entirely from the female perspective for the first time, all in stunningly realistic 3D detail. Complete Anatomy is a revolutionary cloud-based medical education platform from 3D4 Medical by Elsevier and is the No. 1 top-selling medical category app on iPad in the U.S., with over 20 million downloads globally. The launch signifies a major milestone in equal representation by preparing medical, nursing and allied health students with the most complete understanding of the female anatomy. Historically, the full female anatomy has been underrepresented in the study of the human body. Now, educators can choose the sex with which they’d like to teach their full curriculum, in addition to having the option of switching between male and female anatomies to teach comparative differences in sex-specific regions of the body. The Complete Anatomy female model provides educators with a more comprehensive teaching approach that allows them to switch seamlessly between teaching both female and male anatomy. Elizabeth Munn, Managing Director, Global Medical Education, Elsevier, said: “As an advocate for content that is diverse and inclusive, we are thrilled to offer this groundbreaking full female model to allow educators to teach anatomy in an equal and comprehensive way. Complete Anatomy is continuing Elsevier’s rich heritage of innovation in education by delivering on our vision of providing transformative medical education solutions. We are proud to take this step forward in addressing gender bias and believe Complete Anatomy’s female model will have a tremendous impact on the educational experience of medical students worldwide as well as on the outcomes of patients they treat in the future.” Informed by four years of expert research and development, anthropological data from specialist texts, academic papers and customer feedback, the addition of the female model to Complete Anatomy’s 3D platform provides an unprecedented opportunity to study the female form in more detail than before. Complete Anatomy’s female model will benefit all courses that teach anatomy and is an essential virtual tool for learners studying outside the lab who need a deeper understanding of both male and female anatomies. The Complete Anatomy female model includes: The full skeletal system — A complete female skeletal system includes a wide array of unique features, rarely seen in anatomical texts. Sexual differences have been applied to areas such as the pelvis and skull. Long bones have been proportioned, and bone angles accurately reflect the uniquely female architectural skeletal base. Accurate portrayal of muscles — To create an accurate representation of the female anatomy, the overall volume of muscle mass for each muscle has been reduced by roughly 30%, in line with research findings from the broadest demographic of females as compared to males. Visually detailed female-specific regions — The female-specific regions have been created in detail that is equivalent to the male counterpart. Breast tissue can be hemisected or quartered to reveal the underlying tissues with a more accurate distribution and representative state of the mammary glands, now shown as nonlactating, unlike most anatomical resources. The reproductive organs from the internal and external genitalia have been remodeled to accurately show their continued relationship. Comparative functionality — Users can switch between models for comparative study on any part of the male and female forms, compare sexual differences and reveal the origin and distribution of nerves. Users can learn continuity from a “Gray’s Anatomy”-inspired atlas and dissection course, take quizzes and watch videos to test their skills. Lead subject matter expert on the update Yasmin Carter, PhD, Assistant Professor of Translational Anatomy at the UMass Chan Medical School, Worcester, MA, USA said: “One of the inherent dangers in using only the male body as ‘anatomical normal’ and the female body as a variation, is perpetuating sexist attitudes. This unconscious bias will be carried by learners into their future interactions with the body, including potentially with patients. Complete Anatomy is creating a platform of representation that is diverse, balanced, and most importantly, accurate. By giving educators the option to choose the female body as the basis for their students’ education, Elsevier is helping evolve equitable teaching practices by normalizing the female body. Complete Anatomy’s female model will support me in training the next generation of medical professionals to be more appropriate and inclusive.” Elsevier has been working continuously to enhance its global portfolio of medical education solutions, digital learning tools and analytics for medical and nursing students to prepare them for successful careers in health professions. Recently, Elsevier announced the acquisition of Osmosis, a visual learning platform for medical students and professionals, which followed other acquisitions in nursing and health education, including Shadow Health, a developer of virtual nursing simulations, and the 2019 acquisition of 3D4 Medical, the creator of the Complete Anatomy app. In addition, Elsevier launched ClinicalKey Student, an interactive medical education platform equipped with learning tools to support both students and faculty. --- About Complete Anatomy Complete Anatomy from 3D4 Medical by Elsevier is the world's most advanced 3D anatomy platform. The revolutionary cloud-based education platform allows users to investigate the minute detail of the human anatomy in incredible 3D. Complete Anatomy is transforming medical learning and practice across the world, leading the way in the production of groundbreaking 3D medical technology. Featuring over 2.5 million registered customers and over 20 million downloads globally, Complete Anatomy is used daily in over 350 top universities around the world as well as with global clinical organizations. Complete Anatomy’s award-winning software has been featured on stage at Apple and Microsoft events, was honored as the Winner of the Apple Design Awards in 2016, and is the No. 1 top-selling medical category app on iPad in the U.S. 3D4 Medical has been developing medical and anatomical products since 2009 and was acquired by Elsevier in 2019. 3D4 Medical by Elsevier has continued to provide industry-leading innovations that have allowed new ways for students, educators and those in the medical community to learn and understand the human anatomy. To learn more about Complete Anatomy’s female model and the experience it provides users, please visit the 3D4 website. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Media contact Teresa Mueller, Vice President, Global Health Markets Elsevier Communications t.mueller@elsevier.com Contact Details Elsevier Communications Teresa Mueller, Vice President, Global Health Markets +31 6 20987384 t.mueller@elsevier.com Company Website https://www.elsevier.com/

January 10, 2022 09:00 AM Eastern Standard Time

Image

Healthcare

ALDER HEY AND NEEDLESMART PARTNERSHIP AIMS TO REDUCE 100,000 NEEDLESTICK INJURIES TO NHS HEALTHCARE WORKERS

Hong Kong Baptist University research reveals that bisphenol S exposure may promote breast tumour progression and increase cancer risk

Elsevier appoints Laura Hassink as Managing Director, STM Journals

G Medical Innovations (NASDAQ: GMVD) is forecasting incremental Q1 revenues at around $30 MM, based on revenue generated from G Medical Tests and Services’ physical storefront testing locations

McDade Products, LLC and G Medical Tests Secure Additional Purchase Order for $6.5 Million, Reflecting $3.5 Million Gross Margin, to be Delivered in Q1

Most Lives Saved by Organ Transplant in a Single Year

GLOBAL INDUSTRY LEADER NEAL GUTTERSON JOINS GROUNDWORK BIOAG’S ADVISORY BOARD

Biomedical AI entrepreneur Prof. Amir Geva appointed CSO of SleepX

Elsevier launches Complete Anatomy female model, the most advanced full female anatomy model available in the world